IMVT
Price
$15.67
Change
+$0.21 (+1.36%)
Updated
Sep 25 closing price
Capitalization
2.73B
35 days until earnings call
IOVA
Price
$2.02
Change
-$0.10 (-4.72%)
Updated
Sep 25 closing price
Capitalization
730.94M
41 days until earnings call
Interact to see
Advertisement

IMVT vs IOVA

Header iconIMVT vs IOVA Comparison
Open Charts IMVT vs IOVABanner chart's image
Immunovant
Price$15.67
Change+$0.21 (+1.36%)
Volume$2.08M
Capitalization2.73B
Iovance Biotherapeutics
Price$2.02
Change-$0.10 (-4.72%)
Volume$10.01M
Capitalization730.94M
IMVT vs IOVA Comparison Chart in %
Loading...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMVT vs. IOVA commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Buy and IOVA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (IMVT: $15.67 vs. IOVA: $2.02)
Brand notoriety: IMVT and IOVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 133% vs. IOVA: 59%
Market capitalization -- IMVT: $2.73B vs. IOVA: $730.94M
IMVT [@Biotechnology] is valued at $2.73B. IOVA’s [@Biotechnology] market capitalization is $730.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green whileIOVA’s FA Score has 1 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • IOVA’s FA Score: 1 green, 4 red.
According to our system of comparison, both IMVT and IOVA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 3 TA indicator(s) are bullish while IOVA’s TA Score has 3 bullish TA indicator(s).

  • IMVT’s TA Score: 3 bullish, 5 bearish.
  • IOVA’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than IOVA.

Price Growth

IMVT (@Biotechnology) experienced а +1.75% price change this week, while IOVA (@Biotechnology) price change was -8.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +8.82%, and the average quarterly price growth was +54.45%.

Reported Earning Dates

IMVT is expected to report earnings on Oct 31, 2025.

IOVA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMVT($2.73B) has a higher market cap than IOVA($731M). IMVT YTD gains are higher at: -36.698 vs. IOVA (-72.770). IOVA has higher annual earnings (EBITDA): -364.8M vs. IMVT (-470.69M). IMVT has more cash in the bank: 599M vs. IOVA (301M). IMVT has less debt than IOVA: IMVT (98K) vs IOVA (53.2M). IOVA has higher revenues than IMVT: IOVA (242M) vs IMVT (0).
IMVTIOVAIMVT / IOVA
Capitalization2.73B731M374%
EBITDA-470.69M-364.8M129%
Gain YTD-36.698-72.77050%
P/E RatioN/AN/A-
Revenue0242M-
Total Cash599M301M199%
Total Debt98K53.2M0%
FUNDAMENTALS RATINGS
IMVT vs IOVA: Fundamental Ratings
IMVT
IOVA
OUTLOOK RATING
1..100
6855
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
8365
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IOVA's Valuation (21) in the Biotechnology industry is in the same range as IMVT (39) in the null industry. This means that IOVA’s stock grew similarly to IMVT’s over the last 12 months.

IOVA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IMVT (100) in the null industry. This means that IOVA’s stock grew similarly to IMVT’s over the last 12 months.

IOVA's SMR Rating (98) in the Biotechnology industry is in the same range as IMVT (98) in the null industry. This means that IOVA’s stock grew similarly to IMVT’s over the last 12 months.

IOVA's Price Growth Rating (65) in the Biotechnology industry is in the same range as IMVT (83) in the null industry. This means that IOVA’s stock grew similarly to IMVT’s over the last 12 months.

IOVA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IMVT (100) in the null industry. This means that IOVA’s stock grew similarly to IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTIOVA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 24 days ago
76%
Bullish Trend 16 days ago
78%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IOVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NMMGX10.64N/A
N/A
Northern Multi-Manager Glbl Real Estate
JDBRX50.37N/A
N/A
Janus Henderson Balanced R
SIBLX30.58N/A
N/A
Touchstone Balanced Y
IVVIX20.12N/A
N/A
Macquarie Smid Cap Core Fund Class I
QUASX65.20N/A
N/A
AB Small Cap Growth A

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+1.42%
ROIV - IMVT
59%
Loosely correlated
+1.77%
IDYA - IMVT
56%
Loosely correlated
+0.12%
OCUL - IMVT
55%
Loosely correlated
-2.51%
IMNM - IMVT
54%
Loosely correlated
-9.33%
DNLI - IMVT
53%
Loosely correlated
-0.37%
More

IOVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IOVA has been loosely correlated with PLX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IOVA jumps, then PLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IOVA
1D Price
Change %
IOVA100%
-4.95%
PLX - IOVA
47%
Loosely correlated
-0.73%
MGNX - IOVA
41%
Loosely correlated
-4.07%
CDXS - IOVA
41%
Loosely correlated
-3.02%
IMVT - IOVA
40%
Loosely correlated
+1.42%
XNCR - IOVA
40%
Loosely correlated
-1.34%
More